小剂量利妥昔单抗治疗难治性特发性血小板减少性紫瘢  

Lower Dose Rituximab Treatment for Refractory Idiopathic Thrombocytopenic Purpura

作　　者：唐元艳[1] 万琦[1] 虞咏知[1] 董莉[1] 陈盼[1] 梁艳[1] 熊涛[1] 张利铭[1] 黄知平[1] 

机构地区：[1]湖北省荆州市中心医院血液内科,湖北荆州434020

出　　处：《中国临床医学》2010年第6期910-911,共2页Chinese Journal of Clinical Medicine

摘　　要：目的:观察小剂量利妥昔单抗治疗难治性特发性血小板减少性紫癜的临床疗效与不良反应。方法:回顾分析利妥昔单抗治疗4例难治性特发性血小板减少性紫癜患者的临床资料。结果:在4例患者中,1例完全反应,2例有效,1例无效,总反应率为75%;未观察到明显不良反应。结论:小剂量利妥昔单抗治疗难治性特发性血小板减少性紫癜患者是一种安全、可靠、有较好前景的治疗方法。Objective：To investigate the efficacy and safety of lower dose rituximab in the treatment of patients with refractory idiopathic thrombocytopenic purpura（ITP）.Methonds： Four patients with ITP admitted to our hospital were given intravenous rituximab.Their clinical data were analyzed retrospective.Results： A complete response（platelet count greater than 100×109/L） was observed in 1 case,a response（platelet count greater than 30 ×109/L or with a 2-fold or higher increase of the inclusion value without any signs of bleeding） in 2 cases,with an overall response rate of 75%.No infusion related or delayed toxicities attributable to rituximab were experienced by any of the patients.Conclusions： Lower dose rituximab is beneficial for patients with ITP.Lower dose rituximab seems to show similar activity to standard dose.Its side effects are predictable and manageable.

关 键 词：利妥昔单抗 免疫性 血小板减少症 

分 类 号：R554.6[医药卫生—血液循环系统疾病]